Income Statement
Quarterly Data
Difficulty: Beginner
The income statement presents information on the financial results of a company's business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.
Eli Lilly & Co., Consolidated Income Statement (quarterly data)
USD $ in thousands
| 3 months ended | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,355,200 | 5,700,000 | 6,160,700 | 5,658,000 | 5,824,300 | 5,228,300 | 5,760,500 | 5,191,700 | 5,404,800 | 4,865,100 | 5,375,600 | 4,959,700 | 4,978,700 | 4,644,700 | 5,121,300 | 4,875,600 | 4,935,600 | 4,683,100 | 5,808,800 | 5,772,600 | 5,929,700 | 5,602,000 | |||||||||||||||||||||||
| Cost of sales | (1,702,700) | (1,571,300) | (1,624,800) | (1,566,100) | (1,551,600) | (1,327,700) | (1,466,000) | (1,400,900) | (1,465,000) | (1,323,000) | (1,389,200) | (1,236,900) | (1,218,400) | (1,192,700) | (1,253,100) | (1,267,000) | (1,189,700) | (1,222,700) | (1,386,500) | (1,198,100) | (1,165,200) | (1,158,300) | |||||||||||||||||||||||
| Gross margin | 4,652,500 | 4,128,700 | 4,535,900 | 4,091,900 | 4,272,700 | 3,900,600 | 4,294,500 | 3,790,800 | 3,939,800 | 3,542,100 | 3,986,400 | 3,722,800 | 3,760,300 | 3,452,000 | 3,868,200 | 3,608,600 | 3,745,900 | 3,460,400 | 4,422,300 | 4,574,500 | 4,764,500 | 4,443,700 | |||||||||||||||||||||||
| Research and development | (1,333,100) | (1,176,900) | (1,473,200) | (1,319,400) | (1,250,900) | (1,238,300) | (1,450,600) | (1,236,400) | (1,335,900) | (1,221,000) | (1,444,200) | (1,143,400) | (1,169,500) | (1,039,300) | (1,185,700) | (1,243,200) | (1,195,400) | (1,109,300) | (1,475,400) | (1,377,400) | (1,330,400) | (1,348,100) | |||||||||||||||||||||||
| Marketing, selling, and administrative | (1,653,700) | (1,500,000) | (1,780,500) | (1,555,500) | (1,707,400) | (1,544,700) | (1,790,100) | (1,565,400) | (1,622,600) | (1,473,900) | (1,798,400) | (1,575,700) | (1,635,400) | (1,523,500) | (1,799,900) | (1,672,100) | (1,663,900) | (1,484,900) | (1,953,600) | (1,652,400) | (1,867,600) | (1,652,000) | |||||||||||||||||||||||
| Acquired in-process research and development | (1,624,500) | – | (50,000) | (205,000) | – | (857,600) | (30,000) | – | – | – | (199,000) | – | (80,000) | (256,000) | (105,200) | (95,000) | – | – | (57,100) | – | – | – | |||||||||||||||||||||||
| Asset impairment, restructuring, and other special charges | (74,400) | (78,300) | (1,003,200) | (406,500) | (50,000) | (213,900) | (147,600) | (45,500) | (58,000) | (131,400) | (144,900) | (42,400) | (72,400) | (108,000) | (401,000) | (36,300) | – | (31,400) | (35,400) | – | (63,500) | (21,700) | |||||||||||||||||||||||
| Operating income (loss) | (33,200) | 1,373,500 | 229,000 | 605,500 | 1,264,400 | 46,100 | 876,200 | 943,500 | 923,300 | 715,800 | 399,900 | 961,300 | 803,000 | 525,200 | 376,400 | 562,000 | 886,600 | 834,800 | 900,800 | 1,544,700 | 1,503,000 | 1,421,900 | |||||||||||||||||||||||
| Other, net, income (expense) | 38,000 | 67,500 | 55,100 | (13,900) | (3,900) | 15,100 | 15,800 | 27,200 | 21,200 | (149,000) | 44,700 | 86,500 | (123,300) | 92,700 | 137,200 | 93,500 | 53,800 | 56,000 | 9,100 | (31,300) | 11,900 | 529,200 | |||||||||||||||||||||||
| Income before income taxes | 4,800 | 1,441,000 | 284,100 | 591,600 | 1,260,500 | 61,200 | 892,000 | 970,700 | 944,500 | 566,800 | 444,600 | 1,047,800 | 679,700 | 617,900 | 513,600 | 655,500 | 940,400 | 890,800 | 909,900 | 1,513,400 | 1,514,900 | 1,951,100 | |||||||||||||||||||||||
| Income taxes | (264,700) | (223,600) | (1,941,000) | (36,000) | (252,500) | (172,000) | (120,200) | (192,700) | (196,800) | (126,700) | 33,800 | (248,100) | (78,900) | (88,400) | (85,100) | (154,900) | (206,900) | (162,900) | (182,400) | (310,300) | (308,700) | (403,100) | |||||||||||||||||||||||
| Net income (loss) | (259,900) | 1,217,400 | (1,656,900) | 555,600 | 1,008,000 | (110,800) | 771,800 | 778,000 | 747,700 | 440,100 | 478,400 | 799,700 | 600,800 | 529,500 | 428,500 | 500,600 | 733,500 | 727,900 | 727,500 | 1,203,100 | 1,206,200 | 1,548,000 |
| Item | Description | The company |
|---|---|---|
| Revenue | Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. | Eli Lilly & Co.'s revenue declined from Q4 2017 to Q1 2018 but then increased from Q1 2018 to Q2 2018 exceeding Q4 2017 level. |
| Operating income (loss) | The net result for the period of deducting operating expenses from operating revenues. | Eli Lilly & Co.'s operating income (loss) increased from Q4 2017 to Q1 2018 but then declined significantly from Q1 2018 to Q2 2018. |
| Income before income taxes | Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. | Eli Lilly & Co.'s income before income taxes increased from Q4 2017 to Q1 2018 but then declined significantly from Q1 2018 to Q2 2018. |
| Net income (loss) | The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. | Eli Lilly & Co.'s net income (loss) increased from Q4 2017 to Q1 2018 but then slightly declined from Q1 2018 to Q2 2018 not reaching Q4 2017 level. |